60 Degrees Pharmaceuticals Enrolls First Patient in Clinical Trial for Tafenoquine to Treat Babesiosis at Tufts Medical Center
$SXTP
Biotechnology: Pharmaceutical Preparations
Health Care
- The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at Tufts Medical Center in Boston.
- Endpoints are time to sustained clinical resolution of symptoms of babesiosis, and molecular cure as determined by an FDA-approved nucleic acid test (NAT).
- Study is the world's first and only clinical trial evaluating tafenoquine in human babesiosis patients.